EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK

EcoR1 Capital LLC purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 100,000 shares of the company’s stock, valued at approximately $3,256,000. Stoke Therapeutics accounts for approximately 0.1% of EcoR1 Capital LLC’s holdings, making the stock its 24th biggest position.

Several other large investors have also bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in Stoke Therapeutics by 333.8% in the fourth quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after acquiring an additional 1,116,452 shares during the last quarter. State Street Corp raised its position in shares of Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after acquiring an additional 1,072,176 shares during the last quarter. Corient Private Wealth LLC acquired a new position in shares of Stoke Therapeutics in the 2nd quarter valued at $7,489,000. Troluce Capital Advisors LLC acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at $21,255,000. Finally, BVF Inc. IL boosted its position in shares of Stoke Therapeutics by 36.7% in the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after purchasing an additional 608,578 shares during the last quarter.

Stoke Therapeutics Stock Up 0.0%

Shares of NASDAQ STOK opened at $29.31 on Tuesday. Stoke Therapeutics, Inc. has a twelve month low of $12.25 and a twelve month high of $40.22. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -10.43 and a beta of 1.17. The company’s fifty day moving average is $30.41 and its 200-day moving average is $32.10.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The business had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. On average, research analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel owned 18,086 shares in the company, valued at $541,675.70. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the sale, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on STOK shares. Weiss Ratings cut Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, The Goldman Sachs Group began coverage on Stoke Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $44.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.